Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Orelabrutinib Combined With BR/G Followed by Orelabrutinib Maintenance Therapy for Newly Diagnosed Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study

NCT06504940 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT06504940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06504940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Orelabrutinib Combined With BR/G Followed by Orelabrutinib Maintenance Therapy for Newly Diagnosed Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Phase 2
Overall status
Recruiting
Start date
June 28, 2024
Completion date
July 8, 2029
Enrollment
69 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma